
zzso growth factor zzso zzso zzso may overcome chemotherapy resistance by zzso important zzso signals that are zzso activated by an zzso zzso zzso 

This phase I dose escalation trial assessed the safety and efficacy of zzso a novel zzso zzso zzso zzso with zzso an zzso zzso zzso zzso in patients with zzso solid zzso 

zzso patients were treated, 10 with continuous zzso and 7 with intermittent zzso At dose level 1, zzso 280 zzso IV day 1 and zzso 75 zzso PO days zzso zzso zzso in 21 day cycles, two of four patients experienced zzso At dose level zzso zzso 250 zzso every 21 days and zzso 75 zzso two of six patients experienced zzso The study was amended to enroll to zzso zzso zzso zzso day 1 and zzso days zzso of a 21 day zzso Two of seven experienced zzso and the study was zzso One patient with breast cancer had a partial zzso three had stable disease zzso 6 zzso All were treated in the continuous zzso zzso 

Given the marked toxicity in our patient population, the combination of zzso and zzso cannot be recommended for further study with these dosing zzso 

